Conclusions
Alzheimer’s disease, Alzheimer’s clinical syndrome
ADVERSE EVENTS
In patients with mild-to-moderate Alzheimer’s clinical syndrome, neuroEPO plus reduced ADAS-Cog11 score, without related serious adverse events. NeuroEPO plus was approved using the accelerated approval pathway, by the Cuban Regulatory Authority, sanitary register number B-22-016-N07-C. Longer trials are warranted to determine the efficacy and safety of neuroEPO plus in early Alzheimer’s disease.